RecruitingPhase 4NCT06112353

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

Sugammadex VS Neostigmine and Glycopyrrolate Reversal of Neuromuscular Relaxation For Time to Return of Bowel Function After Bowel Resection: Prospective, Randomized, Triple-blinded Clinical Trial For Quality Improvement


Sponsor

University of California, Irvine

Enrollment

128 participants

Start Date

Apr 17, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Age 18 or older
  • Laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission

Exclusion Criteria7

  • Allergy to Rocuronium, Vecuronium, or Sugammadex
  • Bowel resection surgery requiring an ostomy
  • No severe valvulopathy, no systolic heart failure with reduced ejection fraction (HFrEF), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality
  • No autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no COPD with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin
  • Creatinine Clearance (CrCl) of less than 30
  • Pregnancy
  • Incapable of providing consent or understanding the research project

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNeostigmine Injectable Solution

Examine GI-2 recovery

DRUGSugammadex injection

Examine GI-2 recovery


Locations(1)

UC Irvine Medical Center

Orange, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06112353


Related Trials